Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (11-20 of 258) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
High-risk localized prostate cancer: a case for early chemotherapyMartin Gleave, W Kevin Kelly
Prostate Cancer and Prostatic Diseases|December 10, 2003
What's hot in the prostate?Martin Gleave, Christopher P Evans
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 1, 2018
PSA screening: Time to overcome our brand confusionD Robert Siemens, Martin Gleave
FEBS Letters|November 15, 2021
SARS-CoV-2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid dropletsSyam Prakash Somasekharan, Martin Gleave
BJU International|March 24, 2018
Molecular model for neuroendocrine prostate cancer progressionRuiqi Chen, Xuesen Dong, Martin Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancerAmina Zoubeidi, Kim Chi, Martin Gleave
Cancer Chemotherapy and Pharmacology|November 8, 2005
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancerMartin Gleave, Hideaki Miyake, Kim Chi
Current Opinion in Urology|February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancerJoseph Ischia, Fred Saad, Martin Gleave
Current Opinion in Urology|August 12, 2005
Antisense oligonucleotide therapy in the management of bladder cancerAlan So, Palma Rocchi, Martin Gleave
Current Drug Targets|March 20, 2003
Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancerMartin Gleave, Colleen Nelson, Kim Chi
Pageof 26

Showing results (11-20 of 258) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
High-risk localized prostate cancer: a case for early chemotherapyMartin Gleave, W Kevin Kelly
Prostate Cancer and Prostatic Diseases|December 10, 2003
What's hot in the prostate?Martin Gleave, Christopher P Evans
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 1, 2018
PSA screening: Time to overcome our brand confusionD Robert Siemens, Martin Gleave
FEBS Letters|November 15, 2021
SARS-CoV-2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid dropletsSyam Prakash Somasekharan, Martin Gleave
BJU International|March 24, 2018
Molecular model for neuroendocrine prostate cancer progressionRuiqi Chen, Xuesen Dong, Martin Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancerAmina Zoubeidi, Kim Chi, Martin Gleave
Cancer Chemotherapy and Pharmacology|November 8, 2005
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancerMartin Gleave, Hideaki Miyake, Kim Chi
Current Opinion in Urology|February 7, 2013
The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancerJoseph Ischia, Fred Saad, Martin Gleave
Current Opinion in Urology|August 12, 2005
Antisense oligonucleotide therapy in the management of bladder cancerAlan So, Palma Rocchi, Martin Gleave
Current Drug Targets|March 20, 2003
Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancerMartin Gleave, Colleen Nelson, Kim Chi
Pageof 26